Astrazeneca Pharma India Ltd Stock Analysis

BSE: 506820 | NSE: ASTRAZEN | Pharmaceuticals & Drugs | Mid Cap

BSE Share Price 02-Dec-2022 18:01
3275.65 -52.00 (-1.56%)

DeciZen - Make an Informed Decision on Astrazeneca Pharma I

Overall Rating

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

Astrazeneca Pharma I Price Chart

P/E Ratio (SA) :
88.89
Market Cap :
8,189.1 Cr.
52-wk low :
2,437.8
52-wk high :
3,619.7
Bole Toh?

1. Is Astrazeneca Pharma India Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Astrazeneca Pharma India Ltd is a average quality company.

2. Is Astrazeneca Pharma India Ltd undervalued or overvalued?

The key valuation ratios of Astrazeneca Pharma India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Astrazeneca Pharma India Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Astrazeneca Pharma India Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Astrazeneca Pharma I:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Astrazeneca Pharma India Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % -65.4%-9.6%-13%3.6%10.8%11.1%19.7%22%22.7%12.5%-
Value Creation Index -5.7-1.7-1.9-0.8-0.2-0.20.40.60.7-0.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 390474517564544571728832814806901
YoY Gr. Rt. %-21.4%9.1%9%-3.6%5%27.6%14.2%-2.2%-1%-
Adj EPS -37.8-5.2-8.42.28.210.521.628.936.923.936.9
YoY Gr. Rt. %-NANANA274.3%28.1%106.5%34.1%27.4%-35.2%-
BVPS (₹) 39.968.660.362.488.597.9119.5145.1181.8203.8217.5
Adj Net Profit -94.5-13-215.520.426.15472.392.259.792
Cash Flow from Ops. -6-0.8-45.75738.18.85587.4105101-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 8.4%8.2%3.4%-1%
Adj EPS NA24%3.5%-35.2%
BVPS 19.918.219.512.1
Share Price 8% 24.2% 5.5% 5.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % -65.4-9.6-133.610.811.119.721.722.512.317.5
Op. Profit Mgn % -17.5-2.7-2.236.98.29.814.616.710.713.5
Net Profit Mgn % -24.2-2.8-4.113.84.67.48.711.37.410.2
Debt to Equity 00000000000
Working Cap Days 171155173167185216177168193200285
Cash Conv. Cycle 5117111711120-2-16155

Recent Performance Summary

Sales growth is good in last 4 quarters at 15.59%

Return on Equity has declined versus last 3 years average to 17.50%

Sales growth has been subdued in last 3 years 3.42%

Net Profit has been subdued in last 3 years 3.45%

Latest Financials - Astrazeneca Pharma India Ltd.

Standalone Consolidated
TTM EPS (₹) 36.9 -
TTM Sales (₹ Cr.) 901 -
BVPS (₹.) 217.5 -
Reserves (₹ Cr.) 539 -
P/BV 15.06 -
PE 88.89 -
From the Market
52 Week Low / High (₹) 2437.75 / 3619.70
All Time Low / High (₹) 9.00 / 4970.00
Market Cap (₹ Cr.) 8,189
Equity (₹ Cr.) 5
Face Value (₹) 2
Industry PE 37.8

Management X-Ray of Astrazeneca Pharma I :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Astrazeneca Pharma I

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

Astrazeneca Pharma India Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Astrazeneca Pharma I on 02-Dec-2022 18:01 is : 3,275.7.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 02-Dec-2022 18:01 the market cap of Astrazeneca Pharma I stood at ₹ 8,189.1.
The latest PE ratio of Astrazeneca Pharma I as of 02-Dec-2022 18:01 is 88.89.
The latest PB ratio of Astrazeneca Pharma I as of 02-Dec-2022 18:01 is 15.06
The 52-week high of Astrazeneca Pharma I is ₹ 3,619.7 and the 52-week low is ₹ 2,437.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Astrazeneca Pharma I is ₹ 901.0 ( Cr.) .

About Astrazeneca Pharma India Ltd

Astrazeneca Pharma India (AZPIL) incorporated on 11 July, 1979 is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC.

The company’s Global Technology Centre (GTC) in Chennai, is its primary insourced IT facility delivering significant value to the business through an end-to-end, integrated IT service delivery mode. The centre was set up in September 2014 in Chennai, Tamil Nadu, India with the mandate to deliver best in class IT service for the global business.

The company launched its R&D Bangalore in 2017 to support AstraZeneca’s global established medicines portfolio. The R&D Bangalore team provides support across a range of therapy areas, including oncology, respiratory and cardiovascular and metabolic diseases, with a focus on AstraZeneca’s mature brands which are used by patients around the world.

The Global Business Services (GBS), which now houses Global Commercial Operations (GCO), was set up in Chennai in 2017 and has driven efficiency across content management, multichannel marketing and analytics and reporting. GCO Global supports E2E commercial content management to markets - from creation, production, review, process, publishing and reporting. GCO helps multiple markets to avoid duplication of content leading to faster launches and cost savings.

Business area of the company

The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory.

Core Therapy Areas

  • Cardiovascular
  • Oncology
  • Respiratory

Milestones and achievements

  • 1979: Astra IDL formation.
  • 1982: Astra factory foundation.
  • 1992: Launch of Cerviprime, Plendil, Ramace, Rhinocort and Imdur.
  • 2001: Merger of Astra & Zeneca in 1999 globally, formed ‘AstraZeneca’ name in India in 2001.
  • 2015: Launch of Forxiga.
  • 2017: Launch of Tagrisso.
  • 2018: Launch of Xigduo XR.
  • 2018: Launch of first Metabolic Centre of Excellence in India.
  • 2019: Launch of Lynparza.
  • 2020: AstraZeneca India launches Qtern.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now